InvestSMART

Medical Developments International Limited (ASX:MVP)

ALERT: Price-sensitive ASX Announcement for MVP
Current share price for MVP : $0.425 -0.09 (-17.48%)+
Announcement
Release
20 Aug 2026 8:56AM
Price at Release
$0.515
Full Release
download
Summary
Medical Developments International Limited announced its FY26 full year results, reporting a 9% increase in group revenue to $42.6 million. The Pain Management segment saw a 12% revenue increase, and significant growth in the Penthrox product was noted, with a 28% increase in Australian hospital use and an 18% rise in European markets. The company achieved a major milestone with the approval of Penthrox for paediatric use in the UK and Europe. EBIT improved to $0.2 million, and free cash flow significantly increased to $4.2 million. The company also expanded access to Penthrox by having it included in the Pharmaceutical Benefits Scheme for Nurse Practitioners in October 2025.
Key Points
  • Group revenue growth of 9% to $42.6 million.
  • Pain Management segment revenue grew 12%.
  • Penthrox volume growth of 28% in the Australian hospital segment.
  • European in-market Penthrox volume growth of 18%.
  • Penthrox paediatric label approved in the UK and Europe.
  • EBIT improved to $0.2 million.
  • Free cashflow increased to $4.2 million.
  • Penthrox added to the PBS for Nurse Practitioners in October 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.